(NASDAQ: CBUS) Cibus's forecast annual revenue growth rate of 106.6% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.18%.
Cibus's revenue in 2026 is $4,286,000.On average, 6 Wall Street analysts forecast CBUS's revenue for 2026 to be $590,883,179, with the lowest CBUS revenue forecast at $470,050,202, and the highest CBUS revenue forecast at $801,482,157. On average, 6 Wall Street analysts forecast CBUS's revenue for 2027 to be $1,082,382,570, with the lowest CBUS revenue forecast at $748,050,013, and the highest CBUS revenue forecast at $1,382,594,887.
In 2028, CBUS is forecast to generate $3,278,138,354 in revenue, with the lowest revenue forecast at $822,855,015 and the highest revenue forecast at $5,867,460,042.